Tectonic Therapeutic To Make Late-breaking Oral Presentation At ESC Heart Failure 2025 Congress Highlighting Phase 1B Data For TX45

Benzinga · 04/15 12:13

WATERTOWN, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors ("GPCRs"), today announced that it will make a late-breaking oral presentation at the European Society of Cardiology (ESC) Heart Failure 2025 Congress. The presentation will highlight Phase 1b data for TX45, Tectonic's lead asset and a long-acting relaxin therapy as a potential best-in-class therapy for patients with Group 2 PH-HFpEF. The presentation at ESC Heart Failure 2025 will include the full Phase 1b PH-HFpEF cohort results for TX45, expanding on the interim data previously announced by Tectonic on January 30, 2025.

ESC Heart Failure 2025 Presentation Details (being held in Belgrade, Serbia, May 17-20, 2025):

  • Title: Hemodynamic effects of TX45 , a long-acting Fc-relaxin fusion, in Group 2 pulmonary hypertension patients.
  • Presenter: Anthony Muslin, MD, Chief Development Officer
  • Session: Late-breaking science in heart failure, cardiomyopathies, pulmonary hypertension, and valvular heart disease
  • Session Date: Saturday, May 17, 2025
  • Session Time: 4:40 p.m. Central European Time / 10:40 a.m. Eastern Time